Spanish pharmaceutical company PharmaMar said on 26 January 2021 that that peer reviewed journal, Science, has published a paper that confirms that the company's drug Plitidepsin has a "potent preclinical efficacy" against COVID-19, Reuters news agency reported on Tuesday.
In a statement, PharmaMar said the Science paper reported that a study carried out in vitro and in vivo by a team of scientists in New York, San Francisco and Paris showed the drug leads to a reduction of viral replication, resulting in a 99% reduction of viral loads in the lungs of Plitidepsin-treated animals.
PharmaMar quoted Science as saying: "We believe that our data and the initial positive results from PharmaMar's clinical trial suggests that Plitidepsin should be strongly considered for expanded clinical trials for the treatment of COVID-19."
Reportedly, Plitidepsin, already authorised in some markets to treat tumours, blocks a protein associated with the COVID-19 virus. Toxicity of the drug is well known and the doses used in COVID-19 trials are well tolerated in humans.
PharmaMar added that it was in talks with various regulatory agencies to start Phase III trials.
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART